Role of sclerostin and dickkopf-1 in the dramatic alteration in bone mass acquisition in adolescents and young women with recent anorexia nervosa

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages

  Maïmoun, Laurent ^a,b,c   Guillaume, Sébastien ^b   Lefebvre, Patrick ^b   Philibert, Pascal ^b   Bertet, Helena ^b   Picot, Marie Christine ^b,d   Gaspari, Laura ^g   Paris, Françoise ^b,e   Courtet, Philippe ^b   Thomas, Eric ^b   Mariano Goulart, Denis ^a   Bringer, Jacques ^b   Renard, Eric ^b,d,f   Sultan, Charles ^b,e  

^a UNIV MONTPELLIER   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c INSERM   (France)

^d GUI DE CHAULIAC HOSPITAL   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^g DEPARTMENT OF NEUROLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DICKKOPF 1 PROTEIN; ORAL CONTRACEPTIVE AGENT; PARATHYROID HORMONE; SCLEROSTIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADOLESCENT; ADULT; AMENORRHEA; ANOREXIA NERVOSA; ARTICLE; BODY MASS; BODY WEIGHT; BONE DEMINERALIZATION; BONE DENSITY; BONE MASS; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE DURATION; DISEASE SEVERITY; FAT FREE MASS; FAT MASS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOGENESIS; YOUNG ADULT;

EID: 84898440309     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2565     Document Type: Article

References (41)

1. Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab . 1995;80: 898-904.
2. Misra M, Miller KK, Bjornson J, et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab . 2003; 88:5615-5623.
3. Legroux-Grot I, Vignau J, DHerbomez M, et al. Evaluation of bone loss and its mechanisms in anorexia nervosa. Calcif Tissue Int . 2007;81:174-182.
4. Galusca B, Zouch M, Germain N, et al. Constitutional thinness: unusual human phenotype of low bone quality. J Clin Endocrinol Metab . 2008;93:110-117.
5. Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med . 2000;133:790-794.
6. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry . 2007;61:348-358.
7. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab . 1992; 75:1060-1065.
8. Jackowski SA, Erlandson MC, Mirwald RL, et al. Effect of maturational timing on bone mineral content accrual from childhood to adulthood: evidence from 15 years of longitudinal data. Bone . 2011; 48:1178-1185.
9. Cadogan J, Blumsohn A, Barker ME, Eastell R. Alongitudinal study of bone gain in pubertal girls: anthropometric and biochemical correlates. J Bone Miner Res . 1998;13:1602-1612.
10. Misra M, Soyka LA, Miller KK, et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab . 2003;88:3816-3822.
11. Soyka LA, Grinspoon S, Levitsky LL, Herzog DB, Klibanski A. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab . 1999;84:4489-4496.
12. Oswiecimska J, Ziora K, Pluskiewicz W, et al. Skeletal status and laboratory investigations in adolescent girls with anorexia nervosa. Bone . 2007;41:103-110.
13. Milos G, Spindler A, Regsegger P, et al. Cortical and trabecular bone density and structure in anorexia nervosa. Osteoporos Int . 2005;16:783-790.
14. Lucas AR, Melton LJ 3rd, Crowson CS, OFallon WM. Long-term fracture risk among women with anorexia nervosa: a populationbased cohort study. Mayo Clin Proc . 1999;74:972-977.
15. Caillot-Augusseau A, Lafage-Proust MH, Margaillan P, et al. Weight gain reverses bone turnover and restores circadian variation of bone resorption in anorexic patients. Clin Endocrinol (Oxf) . 2000;52:113-121.
16. Baron R, Rawadi G. Targeting the Wnt/-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology . 2007; 148:2635-2643.
17. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest . 2006;116:1202-1209.
18. Betts AM, Clark TH, Yang J, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther . 2010;333:2-13.
19. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res . 2009; 24:578-588.
20. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebocontrolled, randomized study ofAMG785, a sclerostin monoclonal antibody. J Bone Miner Res . 2011;26:19-26.
21. Miller KK, Meenaghan E, Lawson EA, et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab . 2011;96:2081-2088.
22. PillsburyDM,ShelleyWB,KligmanAM.ed. Amanual of cutaneous medicine. Philadelphia, PA: Saunders; 1961.
23. Treasure J, Claudino AM, Zucker N. Eating disorders. Lancet . 2010;375:583-593.
24. Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res . 2011;26:2430-2438.
25. Frisch RE. Pubertal adipose tissue: is it necessary for normal sexual maturation? Evidence from the rat and human female. Fed Proc . 1980;39:2395-2400.
26. Mamoun L, Coste O, Mura T, et al. Specific bone mass acquisition in elite female athletes. J Clin Endocrinol Metab . 2013;98:2844-2853.
27. van Coeverden SC, Netelenbos JC, de Ridder CM, et al. Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf) . 2002;57:107-116.
28. Faje AT, Fazeli PK, Katzman DK, et al. Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone . 2012;51:474-479.
29. Hotta M, Fukuda I, Sato K, Hizuka N, Shibasaki T, Takano K. The relationship between bone turnover and body weight, serum insulinlike growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. J Clin Endocrinol Metab . 2000;85: 200-206.
30. M̈dder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res . 2011;26:373-379.
31. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab . 2010;95:1991-1997.
32. M̈dder UI, Clowes JA, Hoey K, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res . 2011;26:27-34.
33. Kirmani S, Amin S, McCready LK, et al. Sclerostin levels during growth in children. Osteoporos Int . 2012;23:1123-1130.
34. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone . 2005;37:148-158.
35. Drake MT, Srinivasan B, M̈dder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab . 2012;95:5056-5062.
36. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoSOne . 2011;6:e25900.
37. Ross SE, Hemati N, Longo KA, et al. Inhibition of adipogenesis by Wnt signaling. Science . 2000;289:950-953.
38. Bredella MA, Fazeli PK, Miller KK, et al. Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab . 2009;94:2129-2136.
39. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone . 2012;50:739-742.
40. Gatti D, Viapiana O, Fracassi E, et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res . 2012;27:2259-2263.
41. American Psychiatric Association . Diagnostic and statistical manual of mental disorders 4th ed (DSM-IV). Washington, DC: American Psychiatric Association; 1994.